Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Enzo Biochem Launches Test for Measuring Risk of Colorectal Cancer

Published: Thursday, April 12, 2012
Last Updated: Thursday, April 12, 2012
Bookmark and Share
Company developing pipeline of new platforms and assays for molecular diagnostic use.

Enzo Biochem Inc. announced the launch of the ColonSentry™ test for assessing a patient’s risk of having colorectal cancer, the first in a pipeline of new molecular diagnostic products the Company plans for the medical community.
 
“As a pioneer in the use of genomic and genetic information as a catalyst for diagnostic products for delivering better healthcare, the availability of ColonSentry™, which only recently received New York State Department of Health approval, marks another important chapter in the transformation of our Company,” said Barry Weiner, Enzo President.  
 
“We also have, pending for New York State approval, our first assay based test on our new proprietary low cost and highly sensitive AmpiProbe™ nucleic acid amplification and detection technology platform.  Our AmpiProbe™ HCV RNA Quantification assay has been tested over hundreds of clinical samples and found to be reliable, accurate and precise. In addition, our assay was found, as compared to similar diagnostics products, to achieve enhanced sensitivity that can allow for a more convenient and efficient workflow which may utilize significantly less starting material and consumables.  This product is the first of several assays now under development based on the AmpiProbe™ next generation molecular diagnostics platform that are expected to be marketed both nationally and internationally.  
 
“These developments underscore the opportunities available to our Company through the combination of a world class clinical lab and ground breaking life science capability.  Today’s announcement of the effective roll out of ColonSentry™ is a significant achievement pointing towards a highly promising era for Enzo.”
 
ColonSentry™ is a first of its kind blood-based risk stratification test for colorectal cancer.  It utilizes RNA to measure the level of expression of seven specific genes. ColonSentry™ requires only a small sample of blood that can be easily collected during a routine physical exam. It is being made available as a tool to help assess a patients’ risk for colorectal cancer, and thus drive greater compliance for use of colonoscopies, which has been very low, and contribute to earlier detection of colorectal cancer.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
One Giant Leap for the Future of Safe Drug Delivery
Sheffield engineers make major breakthrough in developing silk ‘micro-rockets’ that can be used safely in biological environments.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Fix for 3-Billion-Year-Old Genetic Error
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!